19 pharmaceutical commercial enterprises with revenue of more than 10 billion yuan, one exceeded 100 billion yuan

Pharmaceutical Network Industry Dynamic) It is understood that, as of now, with Huashun pharmaceutical commercial sector of 25 listed enterprises have been 2019 results disclosedIn terms of net profit, only two of the 25 pharmaceutical commercial enterprises lost money, and seven pharmaceutical commercial enterprises reported a year-on-year decline in net profitIn addition, in terms of revenue, there are 19 enterprises with revenue of more than 10 billion yuan, including Shanghai Pharmaceuticals, Kyushu Tong, National Pharmaceutical Stakes, National Pharmaceutical Stakes, including Shanghai Pharmaceuticals even exceeded 100 billion yuanThe companies thatnet profit losses were ST Tiansheng and Ruikang Pharmaceuticals, which lost 223 million yuan and 928 million yuan, respectivelyST Tiansheng's net profit fell as much as 2615.11% year-on-yearshanghai pharmaceuticals exceeded 100 billion yuan in 19 enterprises with revenues of more than 10 billion yuanShanghai Pharma's revenue during the reporting period reached RMB186.566 billion, up 17.27% YoYdata show that Shanghai Pharmaceutical's main business covers the pharmaceutical industry, pharmaceutical business (distribution and retail), is a large pharmaceutical industry group, is also one of the country's four major pharmaceutical circulation enterprises, with a direct network covering 24 provinces and cities in the country intensive and high degree of information of modern drug circulation systemIn 2011, the company achieved the "A-shares plus shares."Shanghai Pharma said in its 2019 annual report that the company actively participated in the selection of distribution companies of the various varieties of the band procurement, in the first batch of 11 pilot cities to win the general name market share has significantly increasedAt the same time, the company actively strive for the second batch of band procurement after the national expansion of distribution opportunities, for the winning enterprises to provide market access, storage and project promotion and other value-added servicesIn addition, the company also through mergers and acquisitions to accelerate the domestic distribution network coverage, complete the acquisition of the sichuan Guojia controlling, complete the jiangsu, Heilongjiang, Jilin and other provinces of the provincial platform construction and network extension layoutKyushu Tong ranked second with revenue of 99.497 billion yuan, and in 2019 Kyushu Tong's tax-bearing sales revenue has exceeded 100 billion yuan, entering the hundreds of billions of "clubs"The annual report shows that in 2019, china's pharmaceutical policy intensive release, 4 plus 7 band volume procurement expansion, etc , the company's main business income grew rapidly The core business varieties Western medicine and traditional Chinese medicine achieved sales revenue of 77.911 billion yuan, up 13.65 percent year-on-year, with a gross profit margin of 8.87 percent, up 0.35 percentage points from a year earlier in addition, in 2019, Kyushu Tong's various channels of business balanced development Sales of medical institutions increased by 20.77%, with sales accounting for 36.18%, up 1.99 percentage points, retail pharmacy channels (wholesale business) increased by 17.65%, sales accounted for 26.75%, up 0.80 percentage points, and the company's general agent business also increased significantly Operating products reached 1013, achieving sales of 3.722 billion yuan, an increase of 26.93 percent over the same period last year, and a gross margin of sales of 15.91 percent National Pharmaceuticalco, followed by China Pharmaceuticals, with revenue of RMB5.2046 million, up 20.69 percent year-on-year In the consistent business composition of China Pharmaceuticals, the distribution sector achieved operating income of RMB40,14 million, up 22.15% YoY, and net profit of RMB846 million, up 18.19% YoY The retail sector achieved operating income of RMB12,754 million, up 17.24% YoY, and net profit of RMB312 million, up 3.37% YoY 's performance as a leader in the pharmaceutical industry is also particularly bright Full-year revenue was RMB44.644 billion, up 15.24% from the previous year By the end of 19th, The total assets of The Pharmaceutical Company amounted to 54.19 billion yuan, with a total ownership of shareholders amounting to 10.537 billion yuan and a total market value of 20.59 billion yuan From the main business structure, merchandise sales are still the main source of revenue for the company In 2019, "Commodity Sales" reported full-year revenue of 46.16 billion yuan, accounting for 97.4% of the company's revenue and 7.5% gross margin.